| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Transplantation | 21 | 2024 | 860 | 3.510 |
Why?
|
| Heart Failure | 37 | 2024 | 2297 | 3.160 |
Why?
|
| Tissue and Organ Procurement | 4 | 2023 | 224 | 1.600 |
Why?
|
| Heart-Assist Devices | 18 | 2024 | 1025 | 1.490 |
Why?
|
| Graft Rejection | 6 | 2017 | 588 | 1.330 |
Why?
|
| Cardiovascular System | 4 | 2023 | 107 | 1.320 |
Why?
|
| Myocardium | 7 | 2018 | 1015 | 0.930 |
Why?
|
| Complement C4b | 2 | 2017 | 5 | 0.870 |
Why?
|
| Transplantation, Heterologous | 1 | 2024 | 256 | 0.860 |
Why?
|
| Lung Transplantation | 2 | 2024 | 322 | 0.820 |
Why?
|
| Cardiology | 7 | 2022 | 507 | 0.810 |
Why?
|
| Ethics, Clinical | 2 | 2022 | 77 | 0.740 |
Why?
|
| Ethics Consultation | 1 | 2022 | 28 | 0.740 |
Why?
|
| Immunohistochemistry | 2 | 2017 | 1695 | 0.660 |
Why?
|
| Decision Making | 3 | 2023 | 656 | 0.630 |
Why?
|
| Dementia | 1 | 2024 | 452 | 0.620 |
Why?
|
| Telemedicine | 2 | 2022 | 436 | 0.620 |
Why?
|
| Palliative Care | 3 | 2024 | 433 | 0.600 |
Why?
|
| Legislation, Medical | 1 | 2018 | 13 | 0.590 |
Why?
|
| Mass Screening | 1 | 2024 | 785 | 0.590 |
Why?
|
| Advance Care Planning | 3 | 2023 | 38 | 0.570 |
Why?
|
| Intra-Aortic Balloon Pumping | 2 | 2015 | 43 | 0.570 |
Why?
|
| Humans | 74 | 2024 | 125156 | 0.520 |
Why?
|
| Forecasting | 1 | 2017 | 351 | 0.510 |
Why?
|
| Informed Consent | 1 | 2018 | 333 | 0.490 |
Why?
|
| Toxoplasmosis | 1 | 2015 | 21 | 0.480 |
Why?
|
| Quality of Life | 3 | 2022 | 1942 | 0.480 |
Why?
|
| Serum Sickness | 1 | 2015 | 2 | 0.480 |
Why?
|
| Antilymphocyte Serum | 1 | 2015 | 56 | 0.470 |
Why?
|
| Mesenteric Artery, Superior | 1 | 2014 | 35 | 0.450 |
Why?
|
| Advance Directives | 3 | 2018 | 33 | 0.440 |
Why?
|
| Patient Positioning | 1 | 2014 | 54 | 0.440 |
Why?
|
| Posture | 1 | 2014 | 154 | 0.440 |
Why?
|
| Cardiomyopathy, Dilated | 2 | 2015 | 213 | 0.430 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2014 | 133 | 0.430 |
Why?
|
| Sinus of Valsalva | 2 | 2003 | 35 | 0.410 |
Why?
|
| Catheterization, Peripheral | 1 | 2014 | 125 | 0.400 |
Why?
|
| Tissue Donors | 4 | 2023 | 494 | 0.390 |
Why?
|
| Cardiac Rehabilitation | 2 | 2022 | 25 | 0.380 |
Why?
|
| Aortic Rupture | 2 | 2003 | 122 | 0.380 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 777 | 0.380 |
Why?
|
| Ventricular Function, Left | 6 | 2022 | 508 | 0.370 |
Why?
|
| Cardiomyopathies | 5 | 2021 | 500 | 0.370 |
Why?
|
| Middle Aged | 29 | 2020 | 26939 | 0.360 |
Why?
|
| Echocardiography | 5 | 2018 | 1054 | 0.360 |
Why?
|
| Echocardiography, Three-Dimensional | 4 | 2017 | 53 | 0.360 |
Why?
|
| Aortic Aneurysm | 2 | 2003 | 240 | 0.340 |
Why?
|
| Aortic Valve Insufficiency | 3 | 2016 | 141 | 0.340 |
Why?
|
| Kidney Transplantation | 4 | 2023 | 641 | 0.330 |
Why?
|
| Heart-Lung Transplantation | 2 | 2022 | 23 | 0.330 |
Why?
|
| United States | 16 | 2024 | 10916 | 0.310 |
Why?
|
| Male | 37 | 2023 | 61508 | 0.290 |
Why?
|
| Cardiovascular Diseases | 2 | 2019 | 1968 | 0.280 |
Why?
|
| Coronary Care Units | 1 | 2007 | 35 | 0.280 |
Why?
|
| Allografts | 2 | 2018 | 191 | 0.270 |
Why?
|
| Postoperative Complications | 3 | 2016 | 3071 | 0.270 |
Why?
|
| Echocardiography, Doppler | 3 | 2016 | 171 | 0.270 |
Why?
|
| Antibodies | 1 | 2008 | 374 | 0.260 |
Why?
|
| American Heart Association | 6 | 2024 | 322 | 0.260 |
Why?
|
| Dexamethasone | 1 | 2007 | 279 | 0.250 |
Why?
|
| Waiting Lists | 2 | 2017 | 227 | 0.250 |
Why?
|
| Physician-Patient Relations | 2 | 2020 | 429 | 0.240 |
Why?
|
| Registries | 4 | 2023 | 1433 | 0.240 |
Why?
|
| Aged | 18 | 2024 | 19878 | 0.230 |
Why?
|
| Biopsy | 3 | 2018 | 1237 | 0.230 |
Why?
|
| Subclavian Artery | 2 | 2015 | 73 | 0.230 |
Why?
|
| Peptide Fragments | 1 | 2008 | 780 | 0.220 |
Why?
|
| Hospitals, General | 1 | 2003 | 23 | 0.220 |
Why?
|
| Stroke Volume | 5 | 2022 | 489 | 0.210 |
Why?
|
| Hospice Care | 1 | 2023 | 31 | 0.210 |
Why?
|
| Adult | 19 | 2023 | 29645 | 0.210 |
Why?
|
| Cardiac Catheterization | 3 | 2017 | 635 | 0.210 |
Why?
|
| Hospitalization | 3 | 2021 | 1781 | 0.210 |
Why?
|
| Abortion, Legal | 1 | 2023 | 8 | 0.210 |
Why?
|
| Retrospective Studies | 11 | 2023 | 16334 | 0.210 |
Why?
|
| Brain Death | 1 | 2023 | 61 | 0.210 |
Why?
|
| Telerehabilitation | 1 | 2022 | 4 | 0.210 |
Why?
|
| Balloon Occlusion | 1 | 2003 | 47 | 0.200 |
Why?
|
| BK Virus | 1 | 2023 | 60 | 0.200 |
Why?
|
| Hemodynamics | 4 | 2017 | 850 | 0.200 |
Why?
|
| Nephritis, Interstitial | 1 | 2023 | 38 | 0.200 |
Why?
|
| Polyomavirus Infections | 1 | 2023 | 90 | 0.190 |
Why?
|
| Female | 29 | 2023 | 66787 | 0.190 |
Why?
|
| Research Report | 4 | 2022 | 75 | 0.190 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2022 | 615 | 0.190 |
Why?
|
| Terminal Care | 1 | 2023 | 112 | 0.190 |
Why?
|
| Graft Survival | 1 | 2023 | 535 | 0.180 |
Why?
|
| Hospital Mortality | 3 | 2021 | 1025 | 0.180 |
Why?
|
| Documentation | 1 | 2022 | 113 | 0.180 |
Why?
|
| Disclosure | 1 | 2022 | 151 | 0.180 |
Why?
|
| Swine | 1 | 2024 | 1207 | 0.170 |
Why?
|
| Kidney Diseases | 1 | 2024 | 479 | 0.170 |
Why?
|
| Medical Futility | 1 | 2020 | 37 | 0.170 |
Why?
|
| Health Care Rationing | 1 | 2020 | 58 | 0.170 |
Why?
|
| Rivaroxaban | 1 | 2020 | 55 | 0.160 |
Why?
|
| Betacoronavirus | 2 | 2020 | 287 | 0.160 |
Why?
|
| Professional-Family Relations | 1 | 2020 | 93 | 0.160 |
Why?
|
| Critical Pathways | 1 | 2020 | 77 | 0.160 |
Why?
|
| Acute Kidney Injury | 2 | 2019 | 635 | 0.160 |
Why?
|
| Factor Xa Inhibitors | 1 | 2020 | 64 | 0.160 |
Why?
|
| Prealbumin | 2 | 2016 | 26 | 0.160 |
Why?
|
| Triage | 1 | 2020 | 137 | 0.160 |
Why?
|
| Pyridones | 1 | 2020 | 118 | 0.160 |
Why?
|
| Cardiotonic Agents | 2 | 2017 | 139 | 0.160 |
Why?
|
| Prognosis | 6 | 2019 | 4642 | 0.160 |
Why?
|
| Amyloid | 2 | 2016 | 65 | 0.150 |
Why?
|
| Pandemics | 3 | 2022 | 1105 | 0.150 |
Why?
|
| Organ Transplantation | 1 | 2021 | 167 | 0.150 |
Why?
|
| Kidney Failure, Chronic | 2 | 2018 | 880 | 0.150 |
Why?
|
| Follow-Up Studies | 4 | 2019 | 5177 | 0.150 |
Why?
|
| Terminology as Topic | 1 | 2020 | 223 | 0.150 |
Why?
|
| Point-of-Care Systems | 2 | 2015 | 175 | 0.150 |
Why?
|
| Echocardiography, Doppler, Color | 3 | 2015 | 112 | 0.150 |
Why?
|
| Resuscitation Orders | 1 | 2018 | 32 | 0.150 |
Why?
|
| Myocardial Perfusion Imaging | 1 | 2018 | 56 | 0.150 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 357 | 0.140 |
Why?
|
| Medicare | 2 | 2018 | 426 | 0.140 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 373 | 0.140 |
Why?
|
| Patient Readmission | 1 | 2021 | 385 | 0.140 |
Why?
|
| Patient Preference | 1 | 2019 | 118 | 0.140 |
Why?
|
| Pyrazoles | 1 | 2020 | 305 | 0.140 |
Why?
|
| Mortality | 1 | 2018 | 238 | 0.130 |
Why?
|
| Amyloid Neuropathies, Familial | 1 | 2016 | 3 | 0.130 |
Why?
|
| Angiopoietin-2 | 1 | 2016 | 13 | 0.130 |
Why?
|
| Assisted Circulation | 1 | 2016 | 36 | 0.130 |
Why?
|
| Endocardium | 3 | 2018 | 51 | 0.130 |
Why?
|
| Transplant Recipients | 1 | 2017 | 217 | 0.130 |
Why?
|
| Aortic Valve | 2 | 2016 | 440 | 0.120 |
Why?
|
| Surveys and Questionnaires | 3 | 2022 | 3733 | 0.120 |
Why?
|
| Cardiac Volume | 1 | 2015 | 17 | 0.120 |
Why?
|
| Echocardiography, Transesophageal | 3 | 2015 | 240 | 0.120 |
Why?
|
| Atovaquone | 1 | 2015 | 9 | 0.120 |
Why?
|
| Predictive Value of Tests | 5 | 2017 | 2174 | 0.120 |
Why?
|
| Shock, Cardiogenic | 1 | 2017 | 192 | 0.120 |
Why?
|
| Ethics, Medical | 1 | 2018 | 396 | 0.120 |
Why?
|
| Neovascularization, Pathologic | 1 | 2016 | 240 | 0.120 |
Why?
|
| Electronic Health Records | 1 | 2022 | 722 | 0.120 |
Why?
|
| Research Design | 1 | 2019 | 695 | 0.120 |
Why?
|
| Vena Cava, Inferior | 1 | 2015 | 103 | 0.120 |
Why?
|
| Mycoses | 1 | 2016 | 119 | 0.120 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2003 | 804 | 0.120 |
Why?
|
| Radiography, Abdominal | 1 | 2014 | 47 | 0.110 |
Why?
|
| Heart Ventricles | 2 | 2017 | 769 | 0.110 |
Why?
|
| Rabbits | 1 | 2015 | 718 | 0.110 |
Why?
|
| Myocardial Infarction | 1 | 2021 | 1043 | 0.110 |
Why?
|
| Blood Transfusion, Autologous | 1 | 2013 | 34 | 0.110 |
Why?
|
| Ultrasonography, Doppler | 1 | 2014 | 195 | 0.110 |
Why?
|
| Amyloidosis | 1 | 2014 | 72 | 0.100 |
Why?
|
| Hemorrhage | 1 | 2016 | 469 | 0.100 |
Why?
|
| Death | 2 | 2023 | 71 | 0.100 |
Why?
|
| Anti-Infective Agents | 1 | 2015 | 265 | 0.100 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2015 | 369 | 0.100 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2018 | 3572 | 0.100 |
Why?
|
| Survival Rate | 4 | 2019 | 2064 | 0.100 |
Why?
|
| Ambulatory Care | 1 | 2015 | 389 | 0.100 |
Why?
|
| C-Reactive Protein | 1 | 2015 | 432 | 0.100 |
Why?
|
| Prospective Studies | 5 | 2017 | 6158 | 0.100 |
Why?
|
| Kidney | 3 | 2024 | 1365 | 0.090 |
Why?
|
| Diabetic Cardiomyopathies | 1 | 2011 | 17 | 0.090 |
Why?
|
| Glycation End Products, Advanced | 1 | 2011 | 25 | 0.090 |
Why?
|
| Coronary Artery Disease | 1 | 2018 | 813 | 0.090 |
Why?
|
| Image Interpretation, Computer-Assisted | 2 | 2017 | 222 | 0.090 |
Why?
|
| Treatment Outcome | 8 | 2023 | 12392 | 0.090 |
Why?
|
| Hypocalcemia | 1 | 2011 | 36 | 0.090 |
Why?
|
| Diagnosis, Differential | 2 | 2014 | 1896 | 0.090 |
Why?
|
| Reoperation | 1 | 2013 | 833 | 0.080 |
Why?
|
| Plasma Exchange | 1 | 2011 | 84 | 0.080 |
Why?
|
| Standard of Care | 2 | 2022 | 130 | 0.080 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2010 | 62 | 0.080 |
Why?
|
| HLA Antigens | 1 | 2011 | 245 | 0.080 |
Why?
|
| Sarcomeres | 1 | 2009 | 31 | 0.080 |
Why?
|
| Mutation | 2 | 2016 | 5848 | 0.080 |
Why?
|
| Animals | 2 | 2024 | 34224 | 0.080 |
Why?
|
| HIV Infections | 1 | 2021 | 1897 | 0.080 |
Why?
|
| Hospital Costs | 2 | 2021 | 180 | 0.080 |
Why?
|
| Severity of Illness Index | 4 | 2015 | 2912 | 0.080 |
Why?
|
| Prosthesis Design | 3 | 2017 | 681 | 0.080 |
Why?
|
| Incidence | 4 | 2019 | 3146 | 0.080 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2009 | 109 | 0.080 |
Why?
|
| Equipment Design | 2 | 2016 | 599 | 0.070 |
Why?
|
| Postoperative Care | 1 | 2010 | 300 | 0.070 |
Why?
|
| Perioperative Care | 1 | 2010 | 195 | 0.070 |
Why?
|
| Autoantibodies | 1 | 2011 | 436 | 0.070 |
Why?
|
| Gadolinium DTPA | 1 | 2008 | 47 | 0.070 |
Why?
|
| Endothelium | 1 | 2008 | 69 | 0.070 |
Why?
|
| Reproducibility of Results | 4 | 2022 | 2892 | 0.070 |
Why?
|
| Methylprednisolone | 1 | 2007 | 92 | 0.070 |
Why?
|
| Staining and Labeling | 1 | 2008 | 187 | 0.070 |
Why?
|
| Tissue Distribution | 1 | 2008 | 391 | 0.070 |
Why?
|
| Communication | 2 | 2023 | 518 | 0.070 |
Why?
|
| Thermodilution | 1 | 2007 | 11 | 0.070 |
Why?
|
| Glycogen Storage Disease Type III | 1 | 2007 | 2 | 0.070 |
Why?
|
| Coronary Circulation | 1 | 2008 | 216 | 0.070 |
Why?
|
| Time Factors | 5 | 2017 | 6333 | 0.070 |
Why?
|
| Natriuretic Agents | 1 | 2007 | 33 | 0.070 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 2102 | 0.060 |
Why?
|
| Sensitivity and Specificity | 3 | 2008 | 2056 | 0.060 |
Why?
|
| Heart | 2 | 2022 | 729 | 0.060 |
Why?
|
| Pacemaker, Artificial | 1 | 2007 | 174 | 0.060 |
Why?
|
| Defibrillators, Implantable | 1 | 2007 | 190 | 0.060 |
Why?
|
| Resource Allocation | 2 | 2020 | 52 | 0.060 |
Why?
|
| Glucocorticoids | 1 | 2007 | 382 | 0.060 |
Why?
|
| Myocardial Ischemia | 1 | 2008 | 344 | 0.060 |
Why?
|
| Review Literature as Topic | 1 | 2024 | 43 | 0.060 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2007 | 312 | 0.060 |
Why?
|
| Physicians, Women | 1 | 2004 | 47 | 0.050 |
Why?
|
| Chicago | 1 | 2003 | 20 | 0.050 |
Why?
|
| Prolapse | 1 | 2003 | 11 | 0.050 |
Why?
|
| Comorbidity | 2 | 2021 | 1534 | 0.050 |
Why?
|
| Societies, Medical | 2 | 2022 | 696 | 0.050 |
Why?
|
| Morals | 1 | 2024 | 69 | 0.050 |
Why?
|
| False Positive Reactions | 1 | 2003 | 144 | 0.050 |
Why?
|
| Uncertainty | 1 | 2024 | 100 | 0.050 |
Why?
|
| Supreme Court Decisions | 1 | 2023 | 15 | 0.050 |
Why?
|
| Career Choice | 1 | 2004 | 148 | 0.050 |
Why?
|
| Social Class | 1 | 2023 | 190 | 0.050 |
Why?
|
| Aortography | 1 | 2003 | 202 | 0.050 |
Why?
|
| Prevalence | 2 | 2021 | 2455 | 0.050 |
Why?
|
| Patient Admission | 1 | 2003 | 184 | 0.050 |
Why?
|
| Muscle Strength | 1 | 2022 | 75 | 0.050 |
Why?
|
| Academic Medical Centers | 1 | 2003 | 308 | 0.050 |
Why?
|
| Cardiopulmonary Bypass | 2 | 2014 | 355 | 0.050 |
Why?
|
| Exercise Test | 2 | 2015 | 254 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2022 | 3428 | 0.040 |
Why?
|
| Heart Atria | 1 | 2003 | 317 | 0.040 |
Why?
|
| Nursing Homes | 1 | 2021 | 93 | 0.040 |
Why?
|
| Hospitals | 1 | 2023 | 389 | 0.040 |
Why?
|
| Activities of Daily Living | 1 | 2022 | 405 | 0.040 |
Why?
|
| Phenotype | 2 | 2021 | 4263 | 0.040 |
Why?
|
| Thromboembolism | 1 | 2020 | 89 | 0.040 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2021 | 267 | 0.040 |
Why?
|
| Warfarin | 1 | 2020 | 119 | 0.040 |
Why?
|
| Feasibility Studies | 2 | 2015 | 762 | 0.040 |
Why?
|
| Coronary Artery Bypass | 1 | 2022 | 514 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2003 | 493 | 0.040 |
Why?
|
| Liver Transplantation | 1 | 2007 | 1036 | 0.040 |
Why?
|
| Ultrasonography | 2 | 2015 | 941 | 0.040 |
Why?
|
| Renal Replacement Therapy | 1 | 2019 | 142 | 0.040 |
Why?
|
| Signal Transduction | 1 | 2010 | 4534 | 0.040 |
Why?
|
| Risk Assessment | 2 | 2017 | 3466 | 0.040 |
Why?
|
| Consensus | 1 | 2021 | 641 | 0.040 |
Why?
|
| Weight Loss | 1 | 2021 | 481 | 0.030 |
Why?
|
| Sex Factors | 1 | 2021 | 1288 | 0.030 |
Why?
|
| Risk Factors | 3 | 2017 | 10310 | 0.030 |
Why?
|
| Anemia | 1 | 2021 | 340 | 0.030 |
Why?
|
| Nervous System Diseases | 1 | 2021 | 375 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2021 | 493 | 0.030 |
Why?
|
| Prosthesis Implantation | 1 | 2018 | 141 | 0.030 |
Why?
|
| Equipment Safety | 1 | 2016 | 36 | 0.030 |
Why?
|
| Thrombin | 1 | 2016 | 60 | 0.030 |
Why?
|
| Ventricular Function, Right | 1 | 2017 | 111 | 0.030 |
Why?
|
| Cannula | 1 | 2016 | 27 | 0.030 |
Why?
|
| Arteriovenous Malformations | 1 | 2016 | 47 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 97 | 0.030 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2015 | 50 | 0.030 |
Why?
|
| Blood Volume Determination | 1 | 2015 | 10 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2018 | 449 | 0.030 |
Why?
|
| Exercise | 1 | 2021 | 816 | 0.030 |
Why?
|
| Image Enhancement | 2 | 2008 | 163 | 0.030 |
Why?
|
| Length of Stay | 1 | 2021 | 1309 | 0.030 |
Why?
|
| Observer Variation | 1 | 2016 | 299 | 0.030 |
Why?
|
| Prosthesis Failure | 1 | 2016 | 158 | 0.030 |
Why?
|
| Cardiac Output | 1 | 2015 | 171 | 0.030 |
Why?
|
| Septal Occluder Device | 1 | 2015 | 42 | 0.030 |
Why?
|
| Biomarkers | 2 | 2016 | 3090 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 715 | 0.030 |
Why?
|
| Disease Progression | 1 | 2021 | 2064 | 0.030 |
Why?
|
| Exercise Tolerance | 1 | 2015 | 85 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2021 | 3300 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2015 | 456 | 0.030 |
Why?
|
| Cause of Death | 1 | 2016 | 475 | 0.030 |
Why?
|
| Ultrafiltration | 1 | 2013 | 13 | 0.030 |
Why?
|
| Jehovah's Witnesses | 1 | 2013 | 15 | 0.030 |
Why?
|
| Adolescent | 2 | 2023 | 19356 | 0.030 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2021 | 726 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2014 | 334 | 0.030 |
Why?
|
| Endothelial Cells | 1 | 2016 | 524 | 0.030 |
Why?
|
| Hypertension | 1 | 2021 | 1329 | 0.020 |
Why?
|
| Creatinine | 1 | 2014 | 389 | 0.020 |
Why?
|
| Stroke | 1 | 2020 | 989 | 0.020 |
Why?
|
| Hemoglobins | 1 | 2013 | 311 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2018 | 854 | 0.020 |
Why?
|
| G-Protein-Coupled Receptor Kinase 2 | 1 | 2010 | 15 | 0.020 |
Why?
|
| Genotype | 1 | 2016 | 2564 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2015 | 979 | 0.020 |
Why?
|
| Pregnancy | 1 | 2023 | 7201 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1437 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 1361 | 0.020 |
Why?
|
| International Cooperation | 1 | 2010 | 156 | 0.020 |
Why?
|
| Cardiac Myosins | 1 | 2009 | 11 | 0.020 |
Why?
|
| Myosin Heavy Chains | 1 | 2009 | 77 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2011 | 666 | 0.020 |
Why?
|
| Infant | 2 | 2018 | 12483 | 0.020 |
Why?
|
| Lymphocytes | 1 | 2010 | 410 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2010 | 445 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 698 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2018 | 6603 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2016 | 4820 | 0.020 |
Why?
|
| Patient Selection | 1 | 2010 | 699 | 0.020 |
Why?
|
| Vasodilator Agents | 1 | 2008 | 206 | 0.020 |
Why?
|
| Calcium | 1 | 2011 | 1102 | 0.020 |
Why?
|
| Ventriculography, First-Pass | 1 | 2005 | 1 | 0.020 |
Why?
|
| Pedigree | 1 | 2009 | 1605 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 874 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2010 | 1196 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 9059 | 0.010 |
Why?
|
| Contrast Media | 1 | 2008 | 479 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2009 | 1021 | 0.010 |
Why?
|
| Career Mobility | 1 | 2004 | 50 | 0.010 |
Why?
|
| Job Satisfaction | 1 | 2004 | 80 | 0.010 |
Why?
|
| Mentors | 1 | 2004 | 149 | 0.010 |
Why?
|
| Child | 2 | 2016 | 24394 | 0.010 |
Why?
|
| Family | 1 | 2004 | 567 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 2009 | 8209 | 0.010 |
Why?
|
| Internship and Residency | 1 | 2004 | 1182 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2009 | 14011 | 0.010 |
Why?
|